Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma

Inclusion Criteria:

• A physician-diagnosed moderate-to-severe asthma for ≥12 months based on GINAguidelines Steps 4 and 5

• Participants with existing treatment with moderate-to-high doses of ICS therapy forin combination with at least 1 but no more than 2 additional controller medicationsat least 3 months with a stable dose ≥1 month prior to Visit 1

• At least 1 asthma exacerbation in the past year, with at least one exacerbationoccurring while on treatment with moderate to high doses of ICS therapy

• ACQ-5 score more than 1.5 at Screening (Visit 1)

Exclusion Criteria:

• Chronic obstructive or other lung diseases (eg, COPD, idiopathic pulmonary fibrosis,etc) which may impair lung function, or another diagnosed pulmonary or systemicdisease.

• Current smoker or former smoker with cessation within 6 months of Screening orhistory of >10 pack-years. Active vaping of any products and/or marijuana smokingwithin 6 months of Screening.

• Participants who experience a deterioration of asthma that results in emergencytreatment or hospitalization, or treatment with systemic steroids within 1 monthprior to the Screening

• Participants who have experienced an upper or lower respiratory tract infectionwithin the 4 weeks prior to Screening

• For participants on chronic OCS use for the maintenance treatment of asthma: historyof a serious infection requiring hospitalization within the past 12 months prior toRandomization (Visit 2).

• Participants with active tuberculosis (TB), latent TB, a history of incompletelytreated TB, suspected extrapulmonary TB infection, or who are at high risk ofcontracting TB (such as close contact with individuals with active or latent TB) orreceived Bacillus Calmette-Guérin (BCG)-vaccination within 12 weeks prior toScreening

• Severe concomitant illness that would in the Investigator's opinion inhibit theparticipant's participation in the study, including for example, but not limited to,hypertension, renal disease, neurological conditions, heart failure and pulmonarydisease

• The above information is not intended to contain all considerations relevant to apatient's potential participation in a clinical trial